

Supplementary Table 1. Antibodies used in this study

Primary Antibody	Company/Catlog No.	Secondary Antibody
SSEA1	Millipore SCR001	#715-095-151 ^a
SSEA4	Millipore SCR001	#715-095-151 ^a
TRA-1-60	Millipore SCR001	#715-095-151 ^a
TRA-1-81	Millipore SCR001	#715-095-151 ^a
OCT3/4	Cell signaling Technology #2750	#711-095-152 ^a
SOX2	Cell Signaling Technology #2748	#711-095-152 ^a
KLF4	Abcam #ab26648	#711-095-152 ^a
NANOG	Abcam #ab21624	#711-095-152 ^a
Beta III tubulin	Abcam #41489	#703-095-155 ^a
CD31	Santa Cruz Biotechnology #SC1506	#705-095-003 ^a
SOX17	R&D Systems #MAB1924	#715-095-151 ^a
HNF3 beta/ FOXA2	Millipore #07-633	#711-095-152 ^a
HNF 4A	Santa Cruz Biotechnology #sc-8987	#711-095-152 ^a
HNF1B	Santa Cruz Biotechnology #sc-7411	#705-095-003 ^a
HNF6	Santa Cruz Biotechnology #sc-13050	#711-095-152 ^a
PDX1	Santa Cruz Biotechnology #sc-25403	#711-075-152 ^a
Insulin	Sigma #I2018	#715-095-151 ^a
C-peptide	Cell Signaling Technology #4593	#711-075-152 ^a
Insulin	Cell Signaling Technology #4590	#711-095-152 ^a
proinsulin /C-peptide	Millipore #CBL94	#715-075-151 ^a
Glucagon	Abcam #ab10988	#715-075-151 ^a
Somatostatin	Dako #A0566	#711-075-152 ^a
Flow Cytometry		
SOX17	R&D Systems #MAB1924	#A11029 ^b
IgG3 Isotype Control	R&D Systems #MAB007	#A11029 ^b
Insulin	Dako Cytomation #A0564	#706-176-148 ^a
OCT4	Millipore #FCMAB113A4	
IgG1 Isotype Control	R&D Systems #IC002G	
CD184 (CXCR4)	BD Pharmingen #55976	
IgG2a, K, Isotype Control	BD Pharmingen #555576	

^aJackson Laboratories, ^bInvitrogen